TherapeuticsMD (TXMD) Operating Income Growth (3y) (2014 - 2026)
Powered by 
Analysis
TherapeuticsMD (TXMD) Operating Income Growth (3y) (2014 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 650.65 Bn | 629.89 Bn | 17.26 Bn | 7.09% |
| 2 | AbbVie | 466.34 Bn | 459.82 Bn | 12.70 Bn | 12.54% |
| 3 | Merck | 362.11 Bn | 355.02 Bn | 12.21 Bn | 51.64% |
| 4 | Novartis Ag | 267.81 Bn | 260.52 Bn | 11.24 Bn | 19.17% |
| 5 | Pfizer | 157.31 Bn | 145.91 Bn | 10.94 Bn | 7.73% |
| 6 | Bristol Myers Squibb | 128.75 Bn | 117.69 Bn | 9.25 Bn | 33.03% |
| 7 | Sanofi | 51.80 Bn | 44.84 Bn | 10.79 Bn | -15.60% |
| 8 | Revolution Medicines | 40.91 Bn | 40.91 Bn | - | - |
| 9 | BeOne Medicines | 39.65 Bn | 34.55 Bn | 1.53 Bn | 44.54% |
| 10 | TherapeuticsMD | 25.35 Mn | 16.16 Mn | - | 30.89% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 30.89% |
| Mar 31, 2026 | 35.28% |
| Dec 31, 2025 | -26.66% |
| Sep 30, 2025 | 60.99% |
| Jun 30, 2025 | 63.97% |
| Mar 31, 2025 | 58.46% |
| Dec 31, 2024 | 73.59% |
| Sep 30, 2024 | 69.49% |
| Jun 30, 2024 | 57.04% |
| Mar 31, 2024 | 66.09% |
| Dec 31, 2023 | 64.03% |
| Sep 30, 2023 | 58.59% |
| Jun 30, 2023 | 62.00% |
| Mar 31, 2023 | 62.59% |
| Dec 31, 2022 | 45.67% |
| Sep 30, 2022 | 18.75% |
| Jun 30, 2022 | 29.07% |
| Mar 31, 2022 | 22.30% |
| Dec 31, 2021 | 2.45% |
| Sep 30, 2021 | -5.13% |